Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.94
0.133.41%
Last update: Dec 15, 11:53 AM
Comments
Loading...
SAB Biotherapeutics (SABS) Stock Price, Quote, News & History
SABSNASDAQ
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy SAB Biotherapeutics (SABS) stock?
You can purchase shares of SAB Biotherapeutics (NASDAQ:SABS) through any online brokerage.
Who are SAB Biotherapeutics (SABS) competitors?
Other companies in SAB Biotherapeutics’s space includes: Molecular Partners AG (NASDAQ:MOLN), Kalaris Therapeutics Inc (NASDAQ:KLRS), Innate Pharma SA (NASDAQ:IPHA), Armata Pharmaceuticals Inc (AMEX:ARMP) and Vistagen Therapeutics Inc (NASDAQ:VTGN).
What is the forecast, or price target, for SAB Biotherapeutics (SABS) stock?
SAB Biotherapeutics has a consensus price target of $9.29.
What is the current price for SAB Biotherapeutics (SABS)?
The stock price for SAB Biotherapeutics (NASDAQ: SABS) is $3.94 last updated December 15, 2025 at 11:53 AM EST.
Does SAB Biotherapeutics (SABS) pay a dividend?
There are no upcoming dividends for SAB Biotherapeutics.
When is SAB Biotherapeutics (NASDAQ:SABS) reporting earnings?
SAB Biotherapeutics does not have any upcoming earnings scheduled.
Is SAB Biotherapeutics (SABS) going to split?
There is no upcoming split for SAB Biotherapeutics.
What sector and industry does SAB Biotherapeutics (SABS) operate in?
SAB Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
